The combination of the spinit® CRP and BC tests allows early diagnosis of patients at greatest risk for Covid-19 
Following the cases that occurred in Wuhan, China at the beginning of the year, several entities have documented strategies that had a very positive and efficient impact in combating this disease. Leveraged by Wuhan's experience, a screening protocol was established in specific screening clinics called Fever clinics, and where the quantification of c-reactive protein and the measurement of the blood count, more specifically the existence or not of Lymphopenia (reduction of Lymphocytes ) are important factors for the decision making process.
The measures to be applied according to the symptoms, such as the values of c-reactive protein and blood count, may require or not require isolation, the performance of the SARS-Cov-2 test or even the admission to an intensive care unit. The screening for the disease, especially in asymptomatic cases, is one of the most important factors in combating Covid-19 and the level of patient inflammation (c-reactive protein) as well as its defence capacity (blood count) can help to detect and classify the general situation of the population.
Through spinit® products, it is possible to test these parameters on an instrument that offers clinically relevant and accurate results with just one drop of blood in 8 minutes. Together with the rapid tests of Ag and IgG + IgM, also commercialized by biosurfit, the combination of these parameters allows a rapid and large-scale risk assessment for decision-making by health professionals according to the public authorities’ contingency plans.
Through spinit® technology and the combination of tests, these packages aim to serve mobile units located in strategic locations, such as large companies in different sectors, with ongoing activities, public and private hospitals, security forces, among others.